GemVax Announces Phase II Results of GV1001 for Alzheimer's Disease Treatment at CTAD 2019
December 11, 2019 at 05:33 am EST
Share
GemVax announced the phase II study of its experimental drug called GV1001, conducted in moderate to severe Alzheimer's disease, met its primary endpoint, as measured by Severe Impairment Battery, or SIB. The SIB score of the control group treated with donepezil only decreased by 7.23, while that of the experimental group treated with GV1001 high dose in combination with donepezil decreased by 0.12. The study clearly demonstrated the beneficial effects of treating Alzheimer's with GV1001.
GemVax & KAEL Co.,Ltd is a Korea-based company mainly engaged in the manufacture of pollution control equipment used in semiconductor manufacturing processes. The Company and its subsidiaries are engaged in the three categories of businesses: pollution control business, which manufactures chemical air (CA) filters, gas scrubbers, resins, coating resins and other environmental equipments and systems; anticancer and anti-inflammation business, which engages in development of cancer vaccines for infectious diseases, such as acquired immune deficiency syndrome (AIDS) and anti-inflammations, and IT business which mainly produces liquid crystal display (LCD) modules. The Company distributes its products within domestic market and to overseas markets.
GEMVAX&KAEL CO.,LTD. 